Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Reports First Quarter 2024 Earnings

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd (HKG:1349) First Quarter 2024 Results

Key Financial Results

• Revenue: CN¥147.6m (down 22% from 1Q 2023).
• Net income: CN¥2.35m (down 73% from 1Q 2023).
• Profit margin: 1.6% (down from 4.6% in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd shares are up 1.9% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd has 3 warning signs (and 1 which is a bit concerning) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.